

## REMARKS/ARGUMENTS

Claims 7-12 have been withdrawn. Applicants reserve their right to file a divisional(s) to any withdrawn subject matter resulting from this restriction requirement.

The Examiner requires restriction the following:

- Group I      Claims 1-6, drawn to a method of treating myelodysplastic syndromes administering a 4-pyridylmethyl-phthalazine derivative, or
- Group II     Claims 7-9 and 11-12, drawn to a combination of a 4-pyridylmethyl-phthalazine derivative and a second compound, and compositions and commercial packages thereof, or
- Group III    Claim 10, drawn to a method of treating myelodysplastic syndromes administering a 4-pyridylmethyl-phthalazine derivative and a second compound in combination.


Also, the Examiner requires election of species for examination purposes.

Applicants elect Group I and elect the species PTK787 without traverse. Claims 1-6 encompass the elected invention.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
\_\_\_\_\_  
Gregory C. Houghton  
Attorney for Applicants  
Reg. No. 47,666

Date: 12/5/07